Posted by Michael Wonder on 03 Apr 2025
Averoa receives positive opinion from the EMA for Xoancyl, an oral therapy for chronic kidney disease
2 April 2025 - Final European Commission decision expected by June 2025; UK regulatory submission foreseen via MHRA’s international recognition procedure.
Averoa today announces a positive opinion from the EMA’s CHMP for Xoancyl, an oral therapy for chronic kidney disease.
